• 1
    Silverman LB, Declerck L, Gelber RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia 1981-1995. Leukemia. 2000; 14: 2247-2256.
  • 2
    Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001; 97: 1211-1218.
  • 3
    Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood. 2004; 104: 2690-2696.
  • 4
    Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009; 360: 2730-2741.
  • 5
    Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008; 111: 4477-4489.
  • 6
    Pieters R, Carroll WL. Biology and treatment of acute lymphoblastic leukemia. Pediatr Clin North Am. 2008; 55: 1-20.
  • 7
    Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone Hyper-CVAD., a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004; 101: 2788-2801.
  • 8
    Goekbuget N, Baumann A, Beck J, et al. PEG-asparaginase in adult acute lymphoblastic leukemia ALL: efficacy and feasibility analysis with increasing dose levels. Blood. 2008; 112. Abstract 302.
  • 9
    de Bont JM, Holt B, Dekker AW, van der Does-van den Berg, Sonneveld P, Pieters R. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004; 18: 2032-2035.
  • 10
    Schiffer CA. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J Clin Oncol. 2003; 21: 760-761.
  • 11
    Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008; 371: 1030-1043.
  • 12
    Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003; 21: 774-780.
  • 13
    Huguet F, Girard N, Guerche CS, Hennequin C, Mornex F, Azria D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol. 2009; 27: 2269-2277.
  • 14
    Huguet F, Raffoux E, Thomas X, et al. Towards a pediatric approach in adults with acute lymphoblastic leukemia ALL.: the GRAALL-2003 Study. Blood. 2006; 108. Abstract 147.
  • 15
    Storring JM, Brandwein J, Gupta V, et al. Treatment of adult acute lymphoblastic leukemia ALL. with a modified DFCI pediatric regimen-The Princess Margaret Experience. Blood. 2006; 108. Abstract 1875.
  • 16
    Ramanujachar R, Richards S, Hann I, et al. Adolescents with acute lymphoblastic leukaemia: Outcome on UK national paediatric ALL97. and adult UKALLXII/E2993. trials. Pediatr Blood Cancer. 2006; 48: 254-261.
  • 17
    Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002; 20: 2464-2471.
  • 18
    Avramis VI, Tiwari PN. Asparaginase native ASNase or pegylated ASNase. in the treatment of acute lymphoblastic leukemia. Int J Nanomedicine. 2006; 1: 241-254.
  • 19
    Oncospar. Summary of Product Characteristics. Sigma-Tau Pharmaceuticals, Inc. 2006.
  • 20
    Pieters R, Appel I, Kuehnel HJ, et al. Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. Blood. 2008; 112: 4832-4838.
  • 21
    Bertrand Y, Thomas X, Baruchel A, et al. GRASPALL 2005.01 Clinical Study L-asparaginase loaded into red blood cells is effective at depleting serum asparagine in children and adults with relapsed acute lymphoblastic leukaemia ALL. Blood. 2008; 112. Abstract 306.
  • 22
    Allas S, Sahakian P, Fichtner I, Abribat T. Pharmacokinetics and pharmacodynamics in mice of a pegylated recombinant Erwinia Chrysanthemi-derived l-asparaginase. Blood. 2009; 114. Abstract 2033.
  • 23
    Miller HK, Salser JS, Balis ME. Amino acid levels following L-asparagine amidohydrolase EC. therapy. Cancer Res. 1969; 29: 183-187.
  • 24
    Avramis VI, Martin-Aragon S, Avramis EV, Asselin BL. Pharmacoanalytical assays of Erwinia asparaginase Erwinase. and pharmacokinetic results in high-risk acute lymphoblastic leukemia HR ALL. patients: simulations of Erwinase population PK-PD models. Anticancer Res. 2007; 27: 2561-2572.
  • 25
    Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer. 1996; 32A: 1544-1550.
  • 26
    Vieira Pinheiro JP, Ahlke E, Nowak-Gottl U, et al. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol. 1999; 104: 313-320.
  • 27
    Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia. 2008; 22: 1665-1679.
  • 28
    Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002; 99: 1986-1994.
  • 29
    Ollenschlager G, Roth E, Linkesch W, Jansen S, Simmel A, Modder B. Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. Eur J Clin Invest. 1988; 18: 512-516.
  • 30
    Broome JD. L-Asparaginase: discovery and development as a tumor-inhibitory agent. Cancer Treat Rep. 1981; 65( suppl 4): 111-114.
  • 31
    Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: pegaspargase Oncaspar. for the first-line treatment of children with acute lymphoblastic leukemia ALL. Oncologist. 2007; 12: 991-998.
  • 32
    Ahlke E, Nowak-Gottl U, Schulze-Westhoff P, et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia. Br J Haematol. 1997; 96: 675-681.
  • 33
    Vieira Pinheiro JP, Wenner K, Escherich G, et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m2. PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer. 2006; 46: 18-25.
  • 34
    Liang DC, Hung IJ, Yang CP, et al. Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: a report from the Taiwan Pediatric Oncology Group. Leukemia. 1999; 13: 155-160.
  • 35
    Ertel IJ, Nesbit ME, Hammond D, Weiner J, Sather H. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Children's Cancer Study Group. Cancer Res. 1979; 39: 3893-3896.
  • 36
    Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986; 315: 657-663.
  • 37
    Sallan SE, Hitchcock-Bryan S, Gelber R, Cassady JR, Frei E,3rd, Nathan DG. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983; 43: 5601-5607.
  • 38
    Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999; 13: 335-342.
  • 39
    Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood. 2002; 99: 2734-2739.
  • 40
    Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007; 109: 896-904.
  • 41
    Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2005; 23: 7161-7167.
  • 42
    Rizzari C, Valsecchi MG, Arico M, et al. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Munster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study—a report from the Associazione Italiana Ematologia Oncologia Pediatrica. J Clin Oncol. 2001; 19: 1297-1303.
  • 43
    Albertsen BK, Schroder H, Jakobsen P, Muller HJ, Carlsen NT, Schmiegelow K. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clin Pharmacol. 2001; 52: 433-437.
  • 44
    Rizzari C, Zucchetti M, Conter V, et al. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol. 2000; 11: 189-193.
  • 45
    Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol. 2004; 26: 217-226.
  • 46
    Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol. 2000; 18: 1525-1532.
  • 47
    Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia. 1998; 12: 660-665.
  • 48
    Hawkins DS, Park JR, Thomson BG, et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res. 2004; 10: 5335-5341.
  • 49
    Wang B, Relling MV, Storm MC, et al. Evaluation of immunologic cross-reaction of antiasparaginase antibodies in acute lymphoblastic leukemia ALL. and lymphoma patients. Leukemia. 2003; 17: 1583-1588.
  • 50
    Albertsen BK, Schroder H, Jakobsen P, et al. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol. 2002; 38: 310-316.
  • 51
    Albertsen BK, Schmiegelow K, Schroder H, et al. Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study. Cancer Chemother Pharmacol. 2002; 50: 117-120.
  • 52
    Nesbit M, Chard R, Evans A, Karon M, Hammond GD. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol. 1979; 1: 9-13.
  • 53
    Albertsen BK, Schroder H, Ingerslev J, et al. Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system. Br J Haematol. 2001; 115: 983-990.
  • 54
    Barry E, DeAngelo DJ, Neuberg D, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol. 2007; 25: 813-819.
  • 55
    Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999; 457: 621-629.
  • 56
    Wenner KA, Vieira Pinheiro JP, Escherich G, et al. Asparagine concentration in plasma after 2,500 IU/m2. PEG-asparaginase i.v. in children with acute lymphoblastic leukemia. Klin Padiatr. 2005; 217: 321-326.
  • 57
    Hak LJ, Relling MV, Cheng C, et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2004; 18: 1072-1077.
  • 58
    Zalewska-Szewczyk B, Andrzejewski W, Mlynarski W, Jedrychowska-Danska K, Witas H, Bodalski J. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma. 2007; 48: 931-936.
  • 59
    Fu CH, Sakamoto KM. PEG-asparaginase. Expert Opin Pharmacother. 2007; 8: 1977-1984.
  • 60
    Zalewska-Szewczyk B, Gach A, Wyka K, Bodalski J, Mlynarski W. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations. Clin Exp Med. 2009; 9: 113-116.
  • 61
    Hempel G, Muller HJ, Lanvers-Kaminsky C, Wurthwein G, Hoppe A, Boos J. A population pharmacokinetic model for pegylated-asparaginase in children. Br J Haematol. 2010; 148: 119-125.
  • 62
    Gadner H, Masera G, Schrappe M, et al. The Eighth International Childhood Acute Lymphoblastic Leukemia Workshop ‘Ponte di legno meeting’. report: Vienna, Austria, April 27-28, 2005. Leukemia. 2006; 20: 9-17.
  • 63
    Alvarez OA, Zimmerman G. Pegaspargase-induced pancreatitis. Med Pediatr Oncol. 2000; 34: 200-205.
  • 64
    Kearney SL, Dahlberg SE, Levy DE, Voss SD, Sallan SE, Silverman LB. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2009; 53: 162-167.
  • 65
    Parsons SK, Skapek SX, Neufeld EJ, et al. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood. 1997; 89: 1886-1895.
  • 66
    Eden OB, Shaw MP, Lilleyman JS, Richards S. Non-randomised study comparing toxicity of Escherichia coli and Erwinia asparaginase in children with leukaemia. Med Pediatr Oncol. 1990; 18: 497-502.
  • 67
    Kwok CS, Kham SK, Ariffin H, Lin HP, Quah TC, Yeoh AE. Minimal residual disease MRD. measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia ALL. Pediatr Blood Cancer. 2006; 47: 299-304.
  • 68
    Vrooman LM, Supko JG, Neuberg DS, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010; 54: 199-205.
  • 69
    Ogawa C, Ohara A, Manabe A, et al. Treatment outcome of discontinued l-asparaginase in children with standard-risk acute lymphoblastic leukemia: Tokyo Children's Cancer Study Group TCCSG. Study L99-15. Blood 2005; 106. Abstract 878.
  • 70
    Schrey D, Borghorst S, Lanvers-Kaminsky C, et al. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 Protocol between 2000 and 2007. Pediatr Blood Cancer. 2010; 54: 952-958.
  • 71
    Armstrong JK, Hempel G, Koling S, et al. Antibody against polyethylene glycol. adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007; 110: 103-111.
  • 72
    Billett AL, Carls A, Gelber RD, Sallan SE. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer. 1992; 70: 201-206.
  • 73
    Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica. 2006; 91: 24-31.